InsiderTrades.com logo
Never thought I’d see this again…
From Porter & Company   |   Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.

MBRX Insider Trading

Insider Ownership Percentage: 6.70%
Insider Buying (Last 12 Months): $159,990.30
Insider Selling (Last 12 Months): $0.00

Moleculin Biotech Insider Trading History Chart

This chart shows the insider buying and selling history at Moleculin Biotech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Moleculin Biotech Share Price & Price History

Current Price: $2.52
Price Change: ▼ Price Decrease of -0.1 (-3.82%)
As of 10/30/2024 01:00 AM ET

This chart shows the closing price history over time for MBRX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Why Buffett, Bezos, & Congress Are Piling Into This One Sector
From InvestorPlace   |   Ad
Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Congress shifting their stocks in a frenzy? And why are they all piling into ONE unique corner of the market…
Click here for the details

Moleculin Biotech Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/26/2023Jonathan P FosterCFOBuy1,932$10.35$19,996.205,370View SEC Filing Icon  
12/26/2023Robert E GeorgeDirectorBuy966$10.35$9,998.10977View SEC Filing Icon  
12/26/2023Walter V KlempCEOBuy12,560$10.35$129,996.0045,392View SEC Filing Icon  
11/25/2022Walter V KlempCEOBuy3,000$19.20$57,600.0027,326View SEC Filing Icon  
11/21/2022Walter V KlempCEOBuy1,500$17.25$25,875.0024,326View SEC Filing Icon  
11/16/2022Walter V KlempCEOBuy5,680$14.55$82,644.0021,176View SEC Filing Icon  
See Full Table
625,000% Gain
From Crypto Swap Profits   |   Ad
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
>> Dive into the Workshop Here

SEC Filings (Institutional Ownership Changes) for Moleculin Biotech (NASDAQ:MBRX)

15.52% of Moleculin Biotech stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at MBRX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Moleculin Biotech Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/15/2024Armistice Capital LLC156,000$0.55M0.0%+5.1%6.747%Search for SEC Filing on Google Icon
2/13/2024Armistice Capital LLC3,207,417$2.75M0.0%N/A9.600%Search for SEC Filing on Google Icon
1/17/2024Atticus Wealth Management LLC50,001$43K0.0%N/A0.168%Search for SEC Filing on Google Icon
5/15/2023Sio Capital Management LLC1,010,956$0.97M0.5%-2.5%3.407%Search for SEC Filing on Google Icon
7/25/2022Walker Asset Management LLC20,708$32K0.0%N/A0.072%Search for SEC Filing on Google Icon
4/20/2022Sigma Planning Corp57,500$0.10M0.0%+33.7%0.201%Search for SEC Filing on Google Icon
2/2/2022Sigma Planning Corp43,000$80K0.0%N/A0.150%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.270,402$0.81M0.0%-2.5%0.947%Search for SEC Filing on Google Icon
9/17/2021Virtu Financial LLC25,302$93K0.0%N/A0.089%Search for SEC Filing on Google Icon
8/16/2021Occudo Quantitative Strategies LP29,188$0.11M0.0%+31.7%0.102%Search for SEC Filing on Google Icon
8/16/2021State Street Corp59,900$0.22M0.0%N/A0.210%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC237,586$0.87M0.0%+35.9%0.835%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.1,047,529$3.84M0.0%+123.6%3.683%Search for SEC Filing on Google Icon
8/12/2021XTX Topco Ltd32,997$0.12M0.0%N/A0.116%Search for SEC Filing on Google Icon
8/5/2021GSA Capital Partners LLP31,120$0.11M0.0%N/A0.109%Search for SEC Filing on Google Icon
5/21/2021Citadel Advisors LLC13,843$56K0.0%N/A0.049%Search for SEC Filing on Google Icon
5/19/2021Squarepoint Ops LLC28,904$0.12M0.0%+134.2%0.102%Search for SEC Filing on Google Icon
5/18/2021Cubist Systematic Strategies LLC26,624$0.11M0.0%N/A0.094%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC13,843$56K0.0%N/A0.049%Search for SEC Filing on Google Icon
5/14/2021Occudo Quantitative Strategies LP22,158$90K0.0%N/A0.078%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp50,731$0.21M0.0%-43.1%0.178%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC174,822$0.71M0.0%-40.6%0.615%Search for SEC Filing on Google Icon
5/7/2021BlackRock Inc.239,326$0.98M0.0%+449.7%0.841%Search for SEC Filing on Google Icon
4/27/2021Harel Insurance Investments & Financial Services Ltd.10,000$0.14M0.0%N/A0.035%Search for SEC Filing on Google Icon
4/14/2021Taylor Cottrill Erickson & Associates Inc.16,964$69K0.0%-83.3%0.060%Search for SEC Filing on Google Icon
2/10/2021Renaissance Technologies LLC948,503$0.76M0.0%+6.4%7.901%Search for SEC Filing on Google Icon
11/13/2020Truist Financial Corp175,000$0.14M0.0%+25.0%0.284%Search for SEC Filing on Google Icon
8/14/2020Bank of America Corp DE39,900$39K0.0%N/A0.066%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Moleculin Biotech logo
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Read More on Moleculin Biotech

Today's Range

Now: $2.52
Low: $2.52
High: $2.66

50 Day Range

MA: $2.50
Low: $2.33
High: $2.84

52 Week Range

Now: $2.52
Low: $2.12
High: $15.75

Volume

15,751 shs

Average Volume

30,397 shs

Market Capitalization

$5.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.86

Who are the company insiders with the largest holdings of Moleculin Biotech?

Moleculin Biotech's top insider investors include:
  1. Walter V Klemp (CEO)
  2. Jonathan P Foster (CFO)
  3. Robert E George (Director)
Learn More about top insider investors at Moleculin Biotech.
Never thought I’d see this again…
From Porter & Company   |   Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.